<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK97333" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK97333/" /><meta name="ncbi_pagename" content="LAMA2-Related Muscular Dystrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>LAMA2-Related Muscular Dystrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="LAMA2-Related Muscular Dystrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2012/06/07" /><meta name="citation_author" content="Susana Quijano-Roy" /><meta name="citation_author" content="Susan E Sparks" /><meta name="citation_author" content="Anne Rutkowski" /><meta name="citation_pmid" content="22675738" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK97333/" /><meta name="citation_keywords" content="Early-Onset Laminin Alpha 2 Deficiency" /><meta name="citation_keywords" content="Laminin Alpha 2-Deficient Congenital Muscular Dystrophy" /><meta name="citation_keywords" content="Late-Onset Laminin Alpha 2 Deficiency" /><meta name="citation_keywords" content="MDC1A" /><meta name="citation_keywords" content="Merosin-Deficient Congenital Muscular Dystrophy Type 1A" /><meta name="citation_keywords" content="Early-Onset Laminin Alpha 2 Deficiency" /><meta name="citation_keywords" content="Laminin Alpha 2-Deficient Congenital Muscular Dystrophy" /><meta name="citation_keywords" content="Merosin-Deficient Congenital Muscular Dystrophy Type 1A" /><meta name="citation_keywords" content="MDC1A" /><meta name="citation_keywords" content="Late-Onset Laminin Alpha 2 Deficiency" /><meta name="citation_keywords" content="Laminin subunit alpha-2" /><meta name="citation_keywords" content="LAMA2" /><meta name="citation_keywords" content="LAMA2-Related Muscular Dystrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="LAMA2-Related Muscular Dystrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Susana Quijano-Roy" /><meta name="DC.Contributor" content="Susan E Sparks" /><meta name="DC.Contributor" content="Anne Rutkowski" /><meta name="DC.Date" content="2012/06/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK97333/" /><meta name="description" content="The clinical manifestations of LAMA2-related muscular dystrophy (LAMA2 MD) range from severe, early-onset congenital muscular dystrophy (CMD) – referred to as early-onset LAMA2-related muscular dystrophy (LAMA2 MD) in this GeneReview – to mild, later childhood-onset limb-girdle type muscular dystrophy – referred to here as late-onset LAMA2-related muscular dystrophy (LAMA2 MD). Children with early-onset LAMA2 MD have profound hypotonia with muscle weakness evident at birth or within the first six months of life, poor spontaneous movements with contractures of the large joints, and weak cry often associated with respiratory failure. Feeding difficulties with failure to thrive, aspiration, and recurrent chest infections are typical. Progressive scoliosis starting in childhood is common. Seizures and, less often, cardiac involvement can occur. Typically, individuals with early-onset LAMA2 MD do not achieve independent ambulation. Intellect is usually normal. Those with limb-girdle type muscular dystrophy have later onset of proximal muscle weakness and delayed motor milestones, but achieve independent ambulation; they may develop a rigid spine syndrome with joint contractures. Progressive respiratory insufficiency and scoliosis can occur." /><meta name="og:title" content="LAMA2-Related Muscular Dystrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="The clinical manifestations of LAMA2-related muscular dystrophy (LAMA2 MD) range from severe, early-onset congenital muscular dystrophy (CMD) – referred to as early-onset LAMA2-related muscular dystrophy (LAMA2 MD) in this GeneReview – to mild, later childhood-onset limb-girdle type muscular dystrophy – referred to here as late-onset LAMA2-related muscular dystrophy (LAMA2 MD). Children with early-onset LAMA2 MD have profound hypotonia with muscle weakness evident at birth or within the first six months of life, poor spontaneous movements with contractures of the large joints, and weak cry often associated with respiratory failure. Feeding difficulties with failure to thrive, aspiration, and recurrent chest infections are typical. Progressive scoliosis starting in childhood is common. Seizures and, less often, cardiac involvement can occur. Typically, individuals with early-onset LAMA2 MD do not achieve independent ambulation. Intellect is usually normal. Those with limb-girdle type muscular dystrophy have later onset of proximal muscle weakness and delayed motor milestones, but achieve independent ambulation; they may develop a rigid spine syndrome with joint contractures. Progressive respiratory insufficiency and scoliosis can occur." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK97333/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mdef-cmd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK97333/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D62DFE040392100000000046D0167.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK97333_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK97333_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/l1cam/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dcm-lmna/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK97333_"><span class="title" itemprop="name"><i>LAMA2</i>-Related Muscular Dystrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Early-Onset Laminin Alpha 2 Deficiency, Laminin Alpha 2-Deficient Congenital Muscular Dystrophy, Late-Onset Laminin Alpha 2 Deficiency, MDC1A, Merosin-Deficient Congenital Muscular Dystrophy Type 1A</div><p class="contrib-group"><span itemprop="author">Susana Quijano-Roy</span>, MD, PhD, <span itemprop="author">Susan E Sparks</span>, MD, PhD, and <span itemprop="author">Anne Rutkowski</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK97333_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK97333_ai__"><div class="contrib half_rhythm"><span itemprop="author">Susana Quijano-Roy</span>, MD, PhD<div class="affiliation small">Centre de R&#x000e9;f&#x000e9;rence des Maladies Neuromusculaires (GNMH)<br />Service de P&#x000e9;diatrie<br />H&#x000f4;pital Raymond Poincar&#x000e9;<br />Garches, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.phpa.cpr@yor-onajiuq.anasus" class="oemail">rf.phpa.cpr@yor-onajiuq.anasus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Susan E Sparks</span>, MD, PhD<div class="affiliation small">Sanofi Genzyme<br />Cambridge, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.emyzneg@skraps.nasus" class="oemail">moc.emyzneg@skraps.nasus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Anne Rutkowski</span>, MD<div class="affiliation small">Cure CMD Chairman, Kaiser Permanente Southern California (SCPMG)<br />Los Angeles, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.dmceruc@ikswoktur.enna" class="oemail">gro.dmceruc@ikswoktur.enna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 7, 2012</span>.</p><p><em>Estimated reading time: 33 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mdef-cmd.Summary" itemprop="description"><h2 id="_mdef-cmd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The clinical manifestations of <i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD) range from severe, early-onset <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy (CMD) &#x02013; referred to as early-onset <i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD) in this <i>GeneReview</i> &#x02013; to mild, later childhood-onset limb-girdle type muscular dystrophy &#x02013; referred to here as late-onset <i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD). Children with early-onset <i>LAMA2</i> MD have profound hypotonia with muscle weakness evident at birth or within the first six months of life, poor spontaneous movements with contractures of the large joints, and weak cry often associated with respiratory failure. Feeding difficulties with failure to thrive, aspiration, and recurrent chest infections are typical. Progressive scoliosis starting in childhood is common. Seizures and, less often, cardiac involvement can occur. Typically, individuals with early-onset <i>LAMA2</i> MD do not achieve independent ambulation. Intellect is usually normal. Those with limb-girdle type muscular dystrophy have later onset of proximal muscle weakness and delayed motor milestones, but achieve independent ambulation; they may develop a rigid spine syndrome with joint contractures. Progressive respiratory insufficiency and scoliosis can occur.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis of <i>LAMA2</i> MD is based on: clinical findings; elevated serum CK concentration; specific abnormal white matter signal on T<sub>2</sub>-weighted MRI by age one year; complete or partial laminin &#x003b1;2 deficiency on immunohistochemical (IHC) staining of muscle and/or skin; and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> mutation of <i>LAMA2</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the laminin subunit alpha-2.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> For infants and children with early-onset <i>LAMA2</i> MD, multidisciplinary care may include: supplemental feeding and gastrostomy; cough assistance, followed by noninvasive ventilation support (intermittent positive pressure breathing [IPPB] or bilevel ventilation) for respiratory insufficiency; physical therapy and casts, splints, or orthotics for joint contractures; trunk orthotics or braces and spinal fusion as needed for scoliosis. Seizures are treated in a routine manner. Those with late-onset laminin &#x003b1;2 deficiency benefit from regular physical therapy to stretch the joints and spine and may need care for progressive respiratory insufficiency and joint and/or spinal deformities.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div>Early-onset <i>LAMA2</i> MD: During the first five years biannual follow up by: a dietician/gastroenterologist to assess nutritional intake and swallowing; a pulmonologist to assess respiratory function; a physical therapist to assess strength and joint range of motion; and an orthopedist to assess the spine. After age five years at least annual follow up is recommended if the disease course is stable. In the absence of cardiac symptoms, evaluation by a cardiologist including electrocardiogram and echocardiogram at age five years, ten years, and then every two years is recommended.</div></li><li class="half_rhythm"><div>Late-onset <i>LAMA2</i> MD: Follow up with a pulmonologist, cardiologist, and physical therapist.</div></li></ul><p><i>Agents/circumstances to avoid:</i> (1) Succinylcholine during induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities; (2) statin, cholesterol-lowering medication because of risk of muscle damage.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>LAMA2</i>-related muscular dystrophy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="mdef-cmd.Diagnosis"><h2 id="_mdef-cmd_Diagnosis_">Diagnosis</h2><div id="mdef-cmd.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p><i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD) manifests in infancy as <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy (CMD) (referred to as early-onset <i>LAMA2</i> MD in this <i>GeneReview</i>) or as childhood onset limb-girdle type muscular dystrophy (referred to as late-onset <i>LAMA2</i> MD in this <i>GeneReview</i>).</p><p>Individuals with early-onset <i>LAMA2</i> MD are often categorized by:</p><ul><li class="half_rhythm"><div>Immunohistochemical (IHC) staining on muscle or skin biopsy as having complete or partial deficiency of laminin &#x003b1;2, the protein encoded by <i>LAMA2</i>;</div></li><li class="half_rhythm"><div>The inability to ambulate (a manifestation of complete laminin &#x003b1;2 deficiency) or ability to ambulate (a manifestation of partial laminin &#x003b1;2 deficiency).</div></li></ul></div><div id="mdef-cmd.Testing"><h3>Testing</h3><p>Serum CK concentration is typically elevated for both complete and partial laminin &#x003b1;2 deficiency.</p><ul><li class="half_rhythm"><div>In the first years of life, serum CK concentration may be more than fourfold normal values [<a class="bk_pop" href="#mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</a>, <a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>].</div></li><li class="half_rhythm"><div>In one study, maximum serum CK concentrations ranged from 593 IU/L to 838 IU/L in partial laminin &#x003b1;2 deficiency and 840 IU/L to 6987 IU/L in complete laminin &#x003b1;2 deficiency [<a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>]; normal range is between 200 and 400 depending on the laboratory.</div></li><li class="half_rhythm"><div>Children with complete laminin &#x003b1;2 deficiency who do not achieve walking usually have a serum CK concentration of more than 1000 IU in the first two years of life, with a subsequent decrease in levels.</div></li></ul><p><b>Immunohistochemistry (IHC) of muscle or skin biopsy.</b> Expression of laminin &#x003b1;2 is evaluated by commercially available antibodies whose epitopes have been mapped; the importance of using antibodies directed against different fragments of the laminin &#x003b1;2 chain has been demonstrated [<a class="bk_pop" href="#mdef-cmd.REF.he.2001.1319">He et al 2001</a>]. Useful antibodies include those directed against (1) the 80-kd fragment of the carboxy-terminal LG region, (2) the 300-kd amino-terminus fragment, and (3) the entire laminin &#x003b1;2 chain (see <a href="#mdef-cmd.Molecular_Genetics">Molecular Genetics</a>, <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>).</p><p>In 51 individuals with confirmed laminin &#x003b1;2 deficiency, 33 had complete laminin &#x003b1;2 deficiency and 13 had partial deficiency on IHC [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p>Note: (1) A consequence of complete deficiency of laminin &#x003b1;2 , encoded by <i>LAMA2</i>, is complete merosin deficiency because laminin &#x003b1;2 is one of three peptide chains that comprise merosin. Merosin (also known as laminin-211) is a heterotrimer comprising the laminin chains &#x003b1;2, &#x003b2;1, and &#x003b3;1, each encoded by a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (see <a href="#mdef-cmd.Molecular_Genetics">Molecular Genetics</a>). Because merosin deficiency can be primary in <i>LAMA2</i>-related muscular dystrophy or secondary in the dystroglycanopathies (also known as &#x003b1;-dystroglycan-related dystrophy), the term &#x0201c;merosin deficiency&#x0201d; is no longer used because it is not sufficiently specific (see <a class="bk_pop" href="#mdef-cmd.REF.hara.2011.939">Hara et al [2011]</a>). Of note, early reports of laminin &#x003b1;2 or merosin deficiency generated confusion because they did not distinguish between a direct result of inactivation of <i>LAMA2</i> and an indirect effect of a dystroglycanopathy. (2) In order to appreciate the reduced laminin &#x003b1;2 chain expression seen in partial laminin &#x003b1;2 deficiency, it may be necessary to use the antibody to the 300-kd fragment. (3) In order to differentiate partial deficiency of laminin &#x003b1;2 caused by mutation of <i>LAMA2</i> from an indirect result of a dystroglycanopathy, additional IHC staining with IgM antibodies against glycosylated epitopes of &#x003b1;-dystroglycan (IIH6 or VIA41) must be used [<a class="bk_pop" href="#mdef-cmd.REF.naom.1998.495">Naom et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.he.2001.1319">He et al 2001</a>]. (4) In laminin &#x003b1;2 deficiency, staining for laminin &#x003b1;4 and &#x003b1;5 (which are upregulated) is increased [<a class="bk_pop" href="#mdef-cmd.REF.sewry.1997.169">Sewry et al 1997</a>, <a class="bk_pop" href="#mdef-cmd.REF.he.2001.1319">He et al 2001</a>].</p><p>Hematoxylin and eosin staining of muscle. Characteristic findings are a dystrophic process early in infancy, including active degeneration, atrophic fibers, increased extracelluar matrix connective tissue, and areas of increased inflammation. Regenerating fibers, while present, are less than anticipated for the degree of degeneration [<a class="bk_pop" href="#mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</a>].</p><p><b>Brain MRI</b></p><ul><li class="half_rhythm"><div><b>Abnormal white matter signal</b> on T<sub>2</sub>-weighted brain MRI is observed in cerebral areas that are myelinated in the developing brain (i.e., subcortical and periventricular areas) with sparing of those areas that are myelinated later in life (i.e., corpus callosum and internal capsule) [<a class="bk_pop" href="#mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</a>]. These abnormalities (likely secondary to leaky basal laminar connections and increased water content) do not represent areas of demyelination and are detected in some children as early as age six months [<a class="bk_pop" href="#mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</a>] and consistently by age one year in those with the early onset form [<a class="bk_pop" href="#mdef-cmd.REF.leite.2005.190">Leite et al 2005</a>]. The brain MRI findings are seen in both complete and partial laminin &#x003b1;2 deficiency [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</div></li><li class="half_rhythm"><div><b>Structural brain abnormalities,</b> observed in 5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, may include occipital pachygyria or agyria and pontocerebellar atrophy with accompanying variable cognitive impairment [<a class="bk_pop" href="#mdef-cmd.REF.mercuri.2001.297">Mercuri et al 2001</a>, <a class="bk_pop" href="#mdef-cmd.REF.aslan.2005.308">Aslan et al 2005</a>].</div></li></ul><div id="mdef-cmd.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Gene.</b>
<i>LAMA2</i> (encoding the laminin subunit &#x003b1;2 protein) is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause <i>LAMA2</i>-related muscular dystrophy.</p><div id="mdef-cmd.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>LAMA2</i>-Related Muscular Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97333/table/mdef-cmd.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mdef-cmd.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Method&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>LAMA2</i></td><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>5</sup></td><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-80%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>7</sup></td><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions&#x000a0;<sup>5</sup></td><td headers="hd_h_mdef-cmd.T.molecular_genetic_testing_use_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-40%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mdef-cmd.TF.1.1"><p class="no_margin">See <a href="/books/NBK97333/#mdef-cmd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="mdef-cmd.TF.1.2"><p class="no_margin">See <a href="#mdef-cmd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="mdef-cmd.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="mdef-cmd.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="mdef-cmd.TF.1.5"><p class="no_margin">Commonly reported pathogenic variants (exact prevalence in <i>LAMA2</i>-related muscular dystrophy population unknown) are discussed in <a href="#mdef-cmd.Molecular_Genetics">Molecular Genetics</a> and <a class="figpopup" href="/books/NBK97333/table/mdef-cmd.T.selected_lama2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figmdefcmdTselectedlama2pathogenicvar" rid-ob="figobmdefcmdTselectedlama2pathogenicvar">Table 2</a> and include c.2901C&#x0003e;A, c.1854_1861dup, c.2048-2049del, c.7750-1713_78899-2153del4987 (<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 56), and c.7881T&#x0003e;G.</p></div></dd><dt>6. </dt><dd><div id="mdef-cmd.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al [1998]</a>, <a class="bk_pop" href="#mdef-cmd.REF.hayashi.2001.350">Hayashi et al [2001]</a>, <a class="bk_pop" href="#mdef-cmd.REF.di_blasi.2005.1582">Di Blasi et al [2005]</a>, <a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al [2008]</a></p></div></dd><dt>7. </dt><dd><div id="mdef-cmd.TF.1.7"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd></dl></div></div></div></div></div><div id="mdef-cmd.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div><b>Clinical examination</b> demonstrating motor delay and weakness or profound hypotonia in an infant without findings that suggest the diagnosis of <a href="/books/n/gene/sma/">spinal muscular atrophy</a> (SMA) (i.e., tongue fasciculation and areflexia)</div></li><li class="half_rhythm"><div><b>Elevated serum CK concentration</b></div></li><li class="half_rhythm"><div><b>Brain MRI</b> demonstrating bilateral white matter high-intensity signal on T<sub>2</sub>-weighted and FLAIR MRI in periventricular areas and subcortical cerebral hemispheres as early as age six months and consistently at age one year</div></li><li class="half_rhythm"><div><b>Muscle biopsy</b> with consistent dystrophic appearance, including degeneration, fiber atrophy, and increased extracellular matrix connective tissue</div></li><li class="half_rhythm"><div><b>Immunohistochemistry (IHC)</b> showing:</div><ul><li class="half_rhythm"><div>Complete or partial laminin &#x003b1;2 deficiency (muscle and skin)</div></li><li class="half_rhythm"><div>Increased expression of laminin &#x003b1;4 and &#x003b1;5</div></li></ul></li><li class="half_rhythm"><div><b><i>LAMA2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></b></div><ul><li class="half_rhythm"><div>If two mutated <i>LAMA2</i> alleles are identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, the diagnosis of <i>LAMA2</i>-related muscular dystrophy is confirmed.</div></li><li class="half_rhythm"><div>If only one <i>LAMA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> should be performed to identify the second mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li></ul></li></ul><p>Note: In those with typical clinical presentation, serum CK concentration, and brain MRI findings, muscle or skin biopsy is not necessary; <i>LAMA2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to confirm the clinical diagnosis.</p><p><b>Carrier testing for at-risk relatives</b> requires prior identification of the pathogenic variants in the family.</p><p>Note: Carriers are heterozygotes for this <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder and are not at risk of developing the disorder.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p><p>Linkage analysis and evaluation of laminin &#x003b1;2 by immunohistochemistry in chorionic villi may be available in certain specialized laboratories [<a class="bk_pop" href="#mdef-cmd.REF.vainzof.2005.588">Vainzof et al 2005</a>].</p></div></div><div id="mdef-cmd.Clinical_Characteristics"><h2 id="_mdef-cmd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="mdef-cmd.Clinical_Description"><h3>Clinical Description</h3><p>The clinical manifestations of <i>LAMA2</i>-related muscular dystrophy range from severe early-onset <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy (CMD) (early-onset <i>LAMA2</i> MD) to mild later childhood-onset limb-girdle type muscular dystrophy (late-onset <i>LAMA2</i> MD).</p><p>Those with severe disease have neonatal profound hypotonia, poor spontaneous movements, weak cry, and respiratory failure [<a class="bk_pop" href="#mdef-cmd.REF.jones.2001.649">Jones et al 2001</a>, <a class="bk_pop" href="#mdef-cmd.REF.gilhuis.2002.30">Gilhuis et al 2002</a>]. Failure to thrive, gastroesophageal reflux, aspiration, and recurrent chest infections necessitating frequent hospitalizations may accompany the early hypotonic presentation. As disease progresses, facial muscle weakness, temporomandibular joint contractures, and macroglossia may further impair feeding and can affect speech.</p><p>Late-onset <i>LAMA2</i> MD is characterized by later-onset proximal weakness and delayed motor milestones. Affected individuals may show muscle hypertrophy and develop a rigid spine syndrome with joint contractures, usually most prominent in the elbows. Progressive respiratory insufficiency and scoliosis can occur [<a class="bk_pop" href="#mdef-cmd.REF.he.2001.1319">He et al 2001</a>] along with cardiac arrhythmia and cardiomyopathy [<a class="bk_pop" href="#mdef-cmd.REF.carboni.2011.826">Carboni et al 2011</a>].</p><p>Affected individuals are often categorized clinically by the ability or inability to achieve independent ambulation. Infants with complete laminin &#x003b1;2 deficiency on IHC staining (see <a href="#mdef-cmd.Testing">Testing</a>) typically have weakness at birth or in the first six months of life and do not achieve independent ambulation, whereas those with partial laminin &#x003b1;2 deficiency are more likely to have a later-onset, milder clinical course and achieve independent ambulation. (See <a href="#mdef-cmd.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a> for more details.)</p><div id="mdef-cmd.EarlyOnset_LAMA2Related_Muscula"><h4>Early-Onset <i>LAMA2</i>-Related Muscular Dystrophy (CMD Phenotype)</h4><p><b>Respiratory involvement</b> in <i>LAMA2</i> MD is caused by a progressively restrictive chest wall that first involves weakness of the intercostal and accessory muscles. Early in childhood the thorax becomes stiff and chest wall compliance decreases, further contributing to alveolar hypoventilation, atelectasis, and mucous plugs with bronchial obstruction. These changes manifest as low lung volumes. Poor secretion clearance resulting from weak cough leads to recurrent chest infection. Swallowing difficulties and gastroesophageal reflux may increase the risk of aspiration. Chest infections may cause atelectasis, which along with limited pulmonary reserve, increases risk of acute respiratory failure in the setting of infection.</p><p>Spinal deformity may result early in thoracic and lumbar lordosis, which contribute to the progressive restrictive respiratory insufficiency. Thoracic lordosis, with or without concomitant scoliosis, may cause the bronchial wall to be compressed by the anterior vertebral bodies.</p><p>In late adolescence, cervical lordosis may progress to severe neck hyperextension with a significant effect on the quality of life, as well as swallowing and feeding difficulties that increase the risk of aspiration.</p><p>The need for ventilatory support is most likely to occur during two time periods [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>]:</p><ul><li class="half_rhythm"><div>Between birth and age five years in the most severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children mainly due to respiratory muscle weakness, hypotonia, and fatigue. Depending on age, total hours of ventilatory support required, frequency of hospitalizations, and institutional practice patterns, ventilatory support may be noninvasive or mechanical with tracheostomy. Respiratory issues in these infants and young children often stabilize in the first years, likely as a result of improved muscle tone.</div></li><li class="half_rhythm"><div>Between ages ten and 15 years due to progressive restrictive lung disease leading to respiratory insufficiency [<a class="bk_pop" href="#mdef-cmd.REF.wallgrenpettersson.2004.56">Wallgren-Pettersson et al 2004</a>]. Most children in this age group with the early onset form do not have typical signs/symptoms of hypercapnia (i.e., headaches, attention difficulties, and drowsiness) but rather the more subtle findings including recurrent respiratory infections, failure to thrive, poor cough, and fatigue with feeding.</div></li></ul><p><b>Feeding difficulties,</b> consistent low weight, failure to thrive, and precipitous drop in weight with infections and hospitalizations are common. <a class="bk_pop" href="#mdef-cmd.REF.philpot.1999a.542">Philpot et al [1999a]</a> reported weight below the third centile and feeding difficulties including: swallowing abnormalities, difficulty chewing, and prolonged feeding time. In a study of 46 individuals with <i>LAMA2</i> MD, 17 required enteral feeding, usually within the first year [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>]. Of note, children with early-onset <i>LAMA2</i> MD do not attain normal weight (see Management, <a href="#mdef-cmd.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p><p><b>Joint contractures</b> that are present in the first year of life progress slowly even in children receiving intensive daily physical therapy. Contractures tend to occur early in the shoulders, elbows, hips, and knees and later in the temporomandibular joints, distal joints, and cervical spine. Contractures often result in significant morbidity and interfere with activities of daily living.</p><p>Hyperlaxity of the distal phalanges of the fingers is observed in a number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children.</p><p><b>Motor developmental milestones</b> are delayed and often arrested. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children do not acquire independent walking.</p><p><a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al [2010]</a> reported only 15% of individuals acquired independent ambulation, the majority of whom (72%) had partial laminin &#x003b1;2 deficiency on muscle biopsy. A smaller proportion gained the ability to walk with assistance but subsequently lost the ability.</p><p>Individuals with complete laminin &#x003b1;2 deficiency were much less likely to achieve independent ambulation than those with partial deficiency.</p><p><b>Scoliosis,</b> often aggravated by thoracic lordosis, is frequently observed from the first decade of life [<a class="bk_pop" href="#mdef-cmd.REF.bentley.2001.22">Bentley et al 2001</a>]. It is slowly progressive and may contribute to respiratory insufficiency by restriction of the thorax and compression of the airway.</p><p><b>Facial muscle weakness</b> and <b>macroglossia</b> may become significant in toddlers and children, resulting in typical elongated myopathic facies, with an open mouth and tongue protrusion.</p><p><b>Limitation of eye movements (ophthalmoparesis)</b> may be evident as early as age two years. Initially, limitation of eye movement is most evident on upward (vertical) gaze; however, over time, lateral gaze may become impaired. Down gaze seems to be preserved, as are pupil size and pupillary reflex; ptosis is not observed [<a class="bk_pop" href="#mdef-cmd.REF.philpot.1999b.81">Philpot et al 1999b</a>].</p><p><b>Central nervous system (CNS).</b> Cognitive abilities are normal in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and do not correlate with brain MRI abnormalities [<a class="bk_pop" href="#mdef-cmd.REF.messina.2010.898">Messina et al 2010</a>]; however, in a small proportion of individuals, intellectual disability and epilepsy were associated with bilateral occipital pachygyria [<a class="bk_pop" href="#mdef-cmd.REF.jones.2001.649">Jones et al 2001</a>] or dysplastic cortical changes affecting predominantly the occipital and temporal regions [<a class="bk_pop" href="#mdef-cmd.REF.sunada.1995.2084">Sunada et al 1995</a>, <a class="bk_pop" href="#mdef-cmd.REF.pini.1996.316">Pini et al 1996</a>, <a class="bk_pop" href="#mdef-cmd.REF.philpot.1999b.81">Philpot et al 1999b</a>, <a class="bk_pop" href="#mdef-cmd.REF.leite.2005.190">Leite et al 2005</a>, <a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p>Cognitive impairment, reported in fewer than 7% of individuals [<a class="bk_pop" href="#mdef-cmd.REF.jones.2001.649">Jones et al 2001</a>, <a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>], ranged from mild intellectual disability to communication difficulties.</p><p>Absence seizures and partial seizures with secondary generalization develop in 8%-20% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children usually in late childhood; because lack of seizures is likely under-reported, the higher figure may be more accurate [<a class="bk_pop" href="#mdef-cmd.REF.jones.2001.649">Jones et al 2001</a>]. Individuals with cortical dysplasia may develop refractory seizures [<a class="bk_pop" href="#mdef-cmd.REF.vigliano.2009.72">Vigliano et al 2009</a>, <a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p><b>A progressive sensorimotor neuropathy</b> with signs of dysmyelinization may be detected in childhood [<a class="bk_pop" href="#mdef-cmd.REF.di_muzio.2003.500">Di Muzio et al 2003</a>]. These abnormalities are usually mild or clinically not significant. In contrast, needle EMG shows myopathic signs in the majority of individuals, even when performed early in infancy [<a class="bk_pop" href="#mdef-cmd.REF.quijanoroy.2004.292">Quijano-Roy et al 2004</a>].</p><p>Cardiac involvement does not seem to be a major complication of <i>LAMA2</i> MD. Although early ultrasound studies in merosin deficiency (in which molecular genetic studies were incomplete) found decreased ejection fraction and subclinical left ventricular hypokinesis in approximately one third of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#mdef-cmd.REF.spyrou.1998.474">Spyrou et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.jones.2001.649">Jones et al 2001</a>], these results have not been confirmed and cardiac failure is rarely reported [<a class="bk_pop" href="#mdef-cmd.REF.gilhuis.2002.30">Gilhuis et al 2002</a>].</p><p>Anecdotal reports have included one report of cardiac arrhythmia requiring ablation or medical treatment and two reports of sudden death with cardiac arrhythmia, one in the context of a viral infection [SJ Quijano-Roy 2010, personal communication] and recently in an adult with partial merosin deficiency [<a class="bk_pop" href="#mdef-cmd.REF.carboni.2011.826">Carboni et al 2011</a>].</p><p>With improved respiratory management resulting in longer survival, cardiac manifestations may be recognized more commonly in older individuals.</p><p>Secondary pulmonary hypertension may be observed as a complication of respiratory insufficiency [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p></div><div id="mdef-cmd.LateOnset_LAMA2Related_Muscular"><h4>Late-Onset <i>LAMA2</i>-Related Muscular Dystrophy (LGMD Phenotype)</h4><p>Rarely individuals with partial laminin &#x003b1;2 deficiency have onset after infancy manifest as delay in walking or proximal muscle weakness, and are typically classified as having limb-girdle muscular dystrophy. Individuals with this milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may show muscle pseudohypertrophy and/or rigid spine. In general, additional findings include high serum creatine kinase (CK) concentrations, dystrophic muscle changes, abnormal brain MRI, and abnormal nerve conduction studies.</p><p>A recent case report describes two sibs with classic brain MRI white matter abnormalities, seizures, and proximal muscle weakness. In addition, muscle histology show dystrophic features, rimmed vacuoles, and partial decrease in laminin &#x003b1;2 staining; molecular testing confirmed the diagnosis [<a class="bk_pop" href="#mdef-cmd.REF.rajakulendran.2011.590">Rajakulendran et al 2011</a>].</p></div><div id="mdef-cmd.Other_Studies_in_Persons_with_L"><h4>Other Studies in Persons with <i>LAMA2</i> MD</h4><p>Visual evoked potentials and somatosensory potentials show increased latency in older children with normal visual function, even in those with white matter involvement of the occipital lobes and abnormal visual evoked potentials [<a class="bk_pop" href="#mdef-cmd.REF.mercuri.1998.399">Mercuri et al 1998</a>].</p><p>Pathophysiology. <i>LAMA2</i> MD is not a true leukodystrophy; the physiologic basis of the white matter abnormalities observed on brain MRI is not fully understood. Although white matter changes were initially thought to represent hypomyelination, recent studies using both brain MR spectroscopy and diffusion weighted imaging have identified abnormal water content thought to be related to leaky basement membrane connections rather than hypomyelination [<a class="bk_pop" href="#mdef-cmd.REF.leite.2005.190">Leite et al 2005</a>, <a class="bk_pop" href="#mdef-cmd.REF.alkan.2007.655">Alkan et al 2007</a>].</p><p>In particular, brain MR spectroscopy (MRS) reveals very low N-acetylaspartate, N-acetylaspartylglutamate, creatine, and phosphocreatine, findings that suggest a relative astrocytosis and an increased water signal with possible edema within the white matter [<a class="bk_pop" href="#mdef-cmd.REF.leite.2005.190">Leite et al 2005</a>]. These findings are hypothesized to result from increased permeability of the blood-brain barrier due to the absence of laminin &#x003b1;2 in the basal lamina of the cells of the cerebral blood vessels.</p><p>Laminin &#x003b1;2 is also present in Schwann cells. Thus, deficiency of laminin &#x003b1;2 may partially explain the progressive sensorimotor axonal polyneuropathy seen in many individuals with laminin &#x003b1;2 deficiency [<a class="bk_pop" href="#mdef-cmd.REF.quijanoroy.2004.292">Quijano-Roy et al 2004</a>]; however, the clinical significance of the neuropathy and its contribution to the primary muscle disorder are not currently understood.</p><p>In post-mortem studies, the white matter of the brain is pale and spongiform with astrocytosis and demyelinization.</p></div></div><div id="mdef-cmd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Prognostication of clinical severity depends on several variables including: age at first symptom onset, presence/absence of the protein laminin &#x003b1;2 on IHC analysis, <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> type, and, if known, effect of the variant on protein function.</p><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations in <i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD) are emerging through publications of small cohorts. A recently launched effort, CMD GaP (<a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and phenotype), led by the National Center for Biotechnology Information (NCBI) and the National Institute of Neurologic Disease and Stroke (NINDS) (both of the National Institutes of Health), Cure CMD, and a consortium of national and international laboratories (<a href="/books/NBK97333/#mdef-cmd.molgen.TA">Table A</a>) will contribute.</p><p>In a study of 51 individuals with confirmed <i>LAMA2</i> MD, those with complete deficiency presented earlier (age &#x0003c;7 days) (p=0.0073), were more likely to lack independent ambulation (p=0.0215), and were more likely to require enteral feeding (p=0.0099) and ventilatory support (p=0.0354) than those with partial laminin &#x003b1;2 deficiency [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p>Complete absence of laminin &#x003b1;2 and the early-onset severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in general are caused by pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants [<a class="bk_pop" href="#mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>]; however, exceptions occur, including an individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a pathogenic nonsense variant who achieved ambulation [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p>Partial deficiency can be caused by homozygosity for <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants and for <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and by compound heterozygosity for a <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variant and an in-frame <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-skipping variant [<a class="bk_pop" href="#mdef-cmd.REF.naom.1998.495">Naom et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>, <a class="bk_pop" href="#mdef-cmd.REF.tezak.2003.103">Tezak et al 2003</a>, <a class="bk_pop" href="#mdef-cmd.REF.siala.2007.199">Siala et al 2007</a>]. However, in-frame deletions involving the G-<a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> that mediates binding to &#x003b1;-dystroglycan and &#x003b1;7&#x003b2;1 integrin result in a severe early-onset <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> even when IHC analysis reveals partial laminin &#x003b1;2 deficiency on muscle biopsy [<a class="bk_pop" href="#mdef-cmd.REF.naom.1998.495">Naom et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>, <a class="bk_pop" href="#mdef-cmd.REF.tezak.2003.103">Tezak et al 2003</a>, <a class="bk_pop" href="#mdef-cmd.REF.siala.2007.199">Siala et al 2007</a>].</p><p>Partial laminin &#x003b1;2 deficiency may also be caused by a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the conserved cysteine residues on the short arm of the laminin &#x003b1;2 protein [<a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>].</p><p>Although the ability to ambulate is generally correlated with the presence of laminin &#x003b1;2 on muscle biopsy, a limited number of children with complete laminin &#x003b1;2 deficiency have achieved ambulation and conversely some children with partial laminin &#x003b1;2 deficiency have had early-onset disease and no ambulation. <a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al [2010]</a> found that among 51 persons studied, two of 33 with absence of laminin &#x003b1;2 staining on muscle biopsy achieved independent ambulation, one with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/frameshift-variant/">frameshift variant</a> and a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant, and one <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a Kenyan <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> (<a class="figpopup" href="/books/NBK97333/table/mdef-cmd.T.selected_lama2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figmdefcmdTselectedlama2pathogenicvar" rid-ob="figobmdefcmdTselectedlama2pathogenicvar">c.7881T&#x0003e;G</a>). Of note, three in this cohort with the Kenyan founder variant did not acquire ambulation, demonstrating the lack of consistent <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> and variability in clinical presentation.</p><p>See <a href="#mdef-cmd.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b> for the phenotypes associated with several commonly reported pathogenic variants.</p></div><div id="mdef-cmd.Nomenclature"><h3>Nomenclature</h3><p><i>LAMA2</i>-related muscular dystrophy is also known as &#x0201c;merosin-deficient <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy type 1A (MDC1A [muscular dystrophy, congenital, type 1A])&#x0201d; in the international classification, based on the observation (prior to discovery of <i>LAMA2</i>) that individuals with CMD often showed complete or partial absence of merosin by IHC analysis of muscle biopsy.</p><p>A nomenclature system that describes which chains are present in each laminin isoform gives merosin the name laminin-211 because it comprises chains &#x003b1;2, &#x003b2;1, and &#x003b3;1.</p><p>Previously the terms "complete and partial merosin deficiency" based on IHC staining were used before it was known that the defect was laminin &#x003b1;2 deficiency. These old diagnostic terms are not relevant now, given that: (1) the diagnosis of <i>LAMA2</i>-related muscular dystrophy can be made with certainty by detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LAMA2</i>; and (2) merosin deficiency can be primary, caused by biallelic pathogenic variants in <i>LAMA2</i>, or secondary (indirect), caused by biallelic pathogenic variants in one of the dystrophinopathy genes (See <a href="#mdef-cmd.Testing">Testing</a>, <b>Immunohistochemistry</b>).</p></div><div id="mdef-cmd.Prevalence"><h3>Prevalence</h3><p>Exact prevalence of early-onset <i>LAMA2</i> MD is unknown. In general, the prevalence of CMDs has been estimated between 0.7/100,000 (based on a 1996 report from northeast Italy that predates <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> [<a class="bk_pop" href="#mdef-cmd.REF.mostacciuolo.1996.277">Mostacciuolo et al 1996</a>]) and 2.5/100,000 (in a study in western Sweden [<a class="bk_pop" href="#mdef-cmd.REF.darin.2000.1">Darin &#x00026; Tulinius 2000</a>]).</p><p>Regional prevalence is variable: early-onset <i>LAMA2</i> MD accounts for about 30% of the CMD cases in European countries, but only 6% in Japan [<a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>].</p></div></div><div id="mdef-cmd.Genetically_Related_Allelic_Dis"><h2 id="_mdef-cmd_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>LAMA2</i>.</p></div><div id="mdef-cmd.Differential_Diagnosis"><h2 id="_mdef-cmd_Differential_Diagnosis_">Differential Diagnosis</h2><p>Early-onset <i>LAMA2</i>-related muscular dystrophy is in the differential diagnosis of infantile hypotonia with or without respiratory distress and delayed acquisition of motor milestones. Late-onset <i>LAMA2</i> MD is in the differential diagnosis of childhood-onset weakness of the limb-girdle type.</p><p><b>Early-onset <i>LAMA2</i> MD</b> needs to be differentiated from:</p><ul><li class="half_rhythm"><div>Other forms of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy (CMD)</div></li><li class="half_rhythm"><div>Congenital myopathies</div></li><li class="half_rhythm"><div>Congenital metabolic myopathies</div></li><li class="half_rhythm"><div><a href="/books/n/gene/myotonic-d/">Congenital myotonic dystrophy</a></div></li><li class="half_rhythm"><div><a href="/books/n/gene/cms/">Congenital myasthenic syndromes</a> (CMS)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/sma/">Spinal muscular atrophy</a> (SMA)</div></li></ul><p>Early-onset <i>LAMA2</i> MD is easily distinguished from the above disorders because they are not typically associated with: (1) high serum CK concentrations, (2) merosin deficiency detected by immunohistochemical (IHC) staining of muscle or skin biopsy, or (3) white matter changes on brain MRI.</p><p>Clinical examination can also assist in distinguishing them from <i>LAMA2</i> MD. Although all may present with profound hypotonia (with frog leg posture of the legs), chest deformity, and breathing and feeding problems, the following findings may be distinguishing:</p><ul><li class="half_rhythm"><div>Congenital myopathies may show some fibrosis on muscle biopsy, but are excluded mainly based on the presence of diagnostic structural abnormalities on light and electron microscopy (e.g., nemaline myopathy, central core myopathy, <a href="/books/n/gene/mtm/">centronuclear/myotubular myopathy</a>, minicore myopathy). These <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> myopathies (as well as the metabolic and myasthenic myopathies) may show progressive improvement of tone and strength; diffuse joint contractures do not occur even in those with severe disease.</div></li><li class="half_rhythm"><div>Distinctive clinical findings may be observed from an early age in some: ophthalmoplegia and facial bulbar weakness in <a href="/books/n/gene/mtm/">centronuclear/myotubular myopathy</a>; facial and bulbar weakness in nemaline myopathy and <a href="/books/n/gene/cms/">congenital myasthenic syndromes</a> (CMS); malignant hyperthermia in central core disease; striking motor variability in CMS and metabolic myopathies.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/sma/">Spinal muscular atrophy</a> (SMA) shows relatively rapid motor impairment and tongue fasciculations. EMG and muscle biopsy findings suggest a denervation-reinnervation profile; nerve conduction studies are normal.</div></li></ul><p>Secondary deficiency of the protein laminin &#x003b1;2 may result from another type of dystroglycanopathy.</p><p><b>Late-onset <i>LAMA2</i> MD</b> (the limb-girdle muscular dystrophy <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>) needs to be differentiated from other forms of limb girdle muscular dystrophy. Elbow contractures, high serum CK concentrations, and prominent spinal rigidity may lead to a phenotype overlapping with <a href="/books/n/gene/edmd/">Emery-Dreifuss myopathy</a> (EDMD); however, in contrast to EDMD, <i>LAMA2</i> MD lacks major cardiac involvement.</p></div><div id="mdef-cmd.Management"><h2 id="_mdef-cmd_Management_">Management</h2><div id="mdef-cmd.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of a child diagnosed with <i>LAMA2</i>-related muscular dystrophy following the initial diagnosis, the following are recommended:</p><ul><li class="half_rhythm"><div>Assessment of feeding, nutrition, and bone health: measurement of weight and serum concentrations of vitamin D and calcium</div></li><li class="half_rhythm"><div>Systematic inquiry of parents/caregivers regarding digestive complications, in particular dysphagia, GE-reflux, and constipation. Frequent choking, prolonged feeding, and nocturnal cough may identify swallowing and gastroesophageal disorders. Additional assessment may include endoscopy, manometry, PH-meter studies, and videofluoroscopy.</div></li><li class="half_rhythm"><div>Lung function tests that ideally include spirometry (forced vital capacity, forced expired volume in the first second [FEV-1]) and assessment of cough effectiveness (cough peak flow and maximum inspiratory and expiratory pressures)</div><ul><li class="half_rhythm"><div>Evaluate older children with an FVC lower than 60% of the predicted value with polysomnography or, if polysomnography is not routinely performed, overnight oximetry.</div></li><li class="half_rhythm"><div>In those using orthopedic trunk braces or orthoses, assess pulmonary function with and without the brace to determine whether thoracic excursion (and thus ventilator function) is impaired.</div></li></ul></li><li class="half_rhythm"><div>Evaluation for nocturnal hypoventilation in children with a history of recurrent respiratory infections, failure to thrive, poor cry, and/or feeding fatigue</div></li><li class="half_rhythm"><div>Physical therapy assessment of muscle strength and joint mobility</div></li><li class="half_rhythm"><div>Assessment of the spine by an orthopedist regarding the need for early bracing</div></li><li class="half_rhythm"><div>Evaluation by a child neurologist for seizures or unexplained fainting or loss of consciousness.</div></li><li class="half_rhythm"><div>Developmental assessment</div></li><li class="half_rhythm"><div>Neuropsychological testing if learning or behavioral deficiencies are identified</div></li><li class="half_rhythm"><div>Evaluation by a cardiologist including electrocardiogram and echocardiogram</div></li><li class="half_rhythm"><div>Evaluation of respite care services for caregivers</div></li><li class="half_rhythm"><div>Educational planning to place the child with necessary support in the least restrictive educational environment</div></li></ul></div><div id="mdef-cmd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="mdef-cmd.EarlyOnset_LAMA2_MD"><h4>Early-Onset <i>LAMA2</i> MD</h4><p><b>Nutrition/weight.</b> In the absence of evidence-based target BMI or weight charts, the recommendation is to weigh the child serially and assess the frequency of chest infections and hospitalizations. Weight needs to increase annually by small increments. Since these children are usually non-ambulatory and muscular mass is reduced, normalization of weight to standard weights is not the goal. In contrast, excess weight may contribute to reduced motor function, resulting in increased respiratory dysfunction.</p><p>If weight plateaus or decreases, assessment of nutrition and diet, speech and swallowing, and respiratory function by a multidisciplinary team of specialists is recommended:</p><ul><li class="half_rhythm"><div>The patient or caregiver may need to be prompted to recall dietary concerns including lengthy meal times, limited food intake, and/or significant constipation [<a class="bk_pop" href="#mdef-cmd.REF.philpot.1999a.542">Philpot et al 1999a</a>]. Non-ambulant school-age children (because they require assistance to use the restroom) may consciously restrict liquid intake. Limited hydration, choice of diet, and lack of movement may all contribute to constipation, leading to further restriction of oral intake.</div></li><li class="half_rhythm"><div>The nutritionist can review dietary fiber, total liquid consumption, and the need for laxatives (e.g., Miralax<sup>&#x000ae;</sup>, macromolecules FORLAX<sup>&#x000ae;</sup>) to optimize caloric intake during periods of growth.</div></li><li class="half_rhythm"><div>If weight continues to decline, respiratory assessment to evaluate for pulmonary infection is indicated.</div></li></ul><p>Adequate weight gain may be achieved by increasing the caloric content of formulas in infants and by supplementary hypercaloric protein drinks in older children.</p><ul><li class="half_rhythm"><div>Infants with persistently poor weight gain and frequent pulmonary infections should be referred to a gastroenterologist:</div></li><li class="half_rhythm"><div>Gastroesophageal reflux is treated as needed.</div></li><li class="half_rhythm"><div>A nasogastric tube or percutaneous gastrostomy may help avoid aspiration pneumonia and improve nutritional status.</div></li><li class="half_rhythm"><div>Failure to thrive may require supplemental feeding and gastrostomy with or without Nissen fundoplication [<a class="bk_pop" href="#mdef-cmd.REF.philpot.1999a.542">Philpot et al 1999a</a>].</div></li><li class="half_rhythm"><div>Children with poor intake or vomiting may require enteral feeding or intravenous fluid therapy to avoid hypoglycemia and metabolic decompensation.</div></li></ul><p>Calcium and vitamin D supplementation is recommended to support bone growth and strength and to prevent future osteopenia.</p><p><b>Respiratory function testing.</b> Training five year olds to perform spirometry during regular clinic visits may allow them to become adept at performing pulmonary function tests by age six years. (Note: A training effect may lead to an initial improvement in spirometric values.) For those who cannot use a standard mouth piece due to facial weakness, a buco-nasal mask adapter or scuba mouth piece can be used.</p><p>Pulmonary function tests ideally include spirometry (forced vital capacity [FVC], forced expired volume in the first second [FEV-1]) and measures of cough effectiveness (cough peak flow and maximum inspiratory and expiratory pressures). Note: In those using orthopedic trunk braces or orthoses, assess pulmonary function with and without the brace to determine if thoracic excursion is impaired.</p><p>An FVC less than 60% of the predicted value has been associated with sleep-disordered breathing; an FVC less than 40% of predicted has been associated with high risk for nocturnal hypoventilation [<a class="bk_pop" href="#mdef-cmd.REF.mellies.2003.123">Mellies et al 2003</a>].</p><ul><li class="half_rhythm"><div>Those with an FVC less than 60% of predicted or clinical evidence of disordered sleep (daytime somnolence, morning headaches, hypercarbia) should undergo an overnight sleep study (polysomnogram) to evaluate for night-time hypoventilation, hypercapnia, and obstructive sleep apnea.</div></li><li class="half_rhythm"><div>Those with an FVC less than 60% of predicted and hypercapnia, hypoxemia, and/or significant aspiration of food or refluxed gastric contents should be referred to a pulmonologist.</div></li><li class="half_rhythm"><div>Assessment of hypoventilation, night-time and daytime hypercapnea is indicated in children with signs of sleep-related difficulties (e.g., morning headaches, attention difficulties, hypersomnolence, increased fatigue), weight loss, recurrent pulmonary infections, a weak cry, and/or FVC less than 60% of predicted.</div></li><li class="half_rhythm"><div>Because early respiratory insufficiency may not be detected by diurnal tests, polysomnography (including end-tidal CO2 measurements) can be used to evaluate for nocturnal hypoventilation and other sleep-related breathing difficulties, such as apnea (both obstructive and central) and hypopnea, which are usually more pronounced during REM sleep. (The predominance of findings in REM sleep may be the result of diminished respiratory drive, atonia of the upper airway and intercostal muscles, and weakness of the diaphragm.)</div></li></ul><p><b>Assistance with coughing.</b> Weak/ineffective cough can lead to progressive atelectasis, infection, and respiratory failure in those with diminished lung capacity.</p><p>Daily intermittent positive pressure breathing (IPPB) may improve diminished compliance, peak cough flow, and ability to clear secretions. It has been shown to promote expansion of the thorax, prevent or treat atelectasis, and decrease the risk of lower-respiratory infections [<a class="bk_pop" href="#mdef-cmd.REF.mellies.2005.543">Mellies et al 2005</a>, <a class="bk_pop" href="#mdef-cmd.REF.wang.2010">Wang et al 2010</a>]. Positive pressure breathing can be administered by IPPB or a mechanical in-exsufflator (Cough Assist), or attained through breath-stacking maneuvers using a bag valve mask. Patients with weak cough (low cough peak flow, maximum and inspiratory pressures &#x0003c;60 cm H2O, and FVCs &#x0003c;60% predicted) can benefit from use of positive pressure breathing once or twice a day and then as needed during respiratory infections. Night-time ventilator support once initiated also helps inflate the lungs, allowing for better tidal volume and ventilation, and thus preventing atelectasis.</p><p>Because of abdominal muscle weakness and the need for high positive pressures, an abdominal belt can lead to better results, efficacy, and tolerance [<a class="bk_pop" href="#mdef-cmd.REF.gu_rin.2010.866">Gu&#x000e9;rin et al 2010</a>].</p><p><b>Noninvasive ventilation support</b> is indicated in the setting of:</p><ul><li class="half_rhythm"><div>Daytime hypercapnea and/or nocturnal hypoventilation</div></li><li class="half_rhythm"><div>Evidence on polysomnogram of sleep-disordered breathing (even without hypoventilation)</div></li><li class="half_rhythm"><div>Recurrent chest infections or atelectasis (in the absence of either daytime hypercapnea or nocturnal hypoventilation) in infants and toddlers [SJ Quijano-Roy, personal communication]</div></li></ul><p>Noninvasive ventilator interfaces include nasal pillows, nasal masks, and full face masks, all of which come with head gear. Of note, it is difficult to fit masks to infants; toddlers often fight the masks.</p><p>In children, alternating mask interfaces is recommended to prevent the progressive under-bite and midface hypoplasia that result from the bone remodeling associated with long-term use of nasal masks from an early age. Although the nasal mask causes more bite and mid-face problems than does the full face mask, the full face mask should be used with caution because of the risk of suffocation in a child who vomits into the mask and is unable to remove it.</p><p>In patients with severe lordosis/scoliosis and chronic cough or recurrent infections, chest CT may be needed to evaluate for chronic atelectasis and airway compression by the vertebral bodies</p><p>During adolescence ventilatory support is often only needed during sleep with noninvasive pressure support. Assessment of daytime hypercapnea is needed beginning in late adolescence or if patient experiences increasing fatigue, chest infections, or failure to thrive. If daytime ventilation is required, ventilation via tracheostomy may be indicated.</p><p><b>Joint contractures.</b> Physical therapy including daily stander placement, stretching activities, and pool (swimming) therapy can assist in maintenance of some range of motion.</p><p>Splints, orthoses, and night positioning by casts are used to prevent progression of joint deformities.</p><p>Non-ambulant children require standing frames for postural support.</p><p>Durable medical equipment support including power wheelchair fitting is essential for non-ambulant toddlers.</p><p><b>Scoliosis</b> may need orthopedic and surgical treatment [<a class="bk_pop" href="#mdef-cmd.REF.bentley.2001.22">Bentley et al 2001</a>]. When needed, specific trunk orthotics or braces that do not restrict the thorax either through compression or limitation of thoracic movements are recommended [<a class="bk_pop" href="#mdef-cmd.REF.wang.2010">Wang et al 2010</a>]. Their use may improve upright posture and delay spinal fusion until early puberty, providing that bracing does not interfere with respiration by causing chest compression [<a class="bk_pop" href="#mdef-cmd.REF.wang.2010">Wang et al 2010</a>].</p><p>If cervical lordosis progresses in late adolescence, posterior head support (using trunk braces or wheelchair supports) can prevent neck hyperextension.</p><p><b>Cardiomyopathy.</b> Right heart failure due to respiratory insufficiency requires adequate mechanical ventilation. Primary left heart failure or rhythm disturbances require typical age-appropriate treatment.</p><p>Seizures are generally well controlled with routine administration of antiepileptic drugs. Refractory seizures in those with cortical dysplasia may require polytherapy.</p><p><b>Developmental delay/cognitive impairment.</b> Early intervention with physical, occupational, and speech therapy along with a multidisciplinary medical team provide the best possible outcome.</p><p><b>Other.</b> Surgery to correct facial function and address cosmetic concerns has been performed [<a class="bk_pop" href="#mdef-cmd.REF.jones.2012.e141">Jones &#x00026; Waite 2012</a>].</p></div><div id="mdef-cmd.LateOnset_LAMA2_MD"><h4>Late-Onset <i>LAMA2</i> MD</h4><p>These patients need mainly respiratory and orthopedic care due to the risk of progressive respiratory insufficiency and joint and spinal deformities. Regular physical therapy for stretching limbs, shoulder and pelvic girdle, and spine is mandatory.</p><p>Antiepileptic drugs should be used to treat seizures.</p></div></div><div id="mdef-cmd.Surveillance"><h3>Surveillance</h3><p>Standards of care have been reviewed recently [<a class="bk_pop" href="#mdef-cmd.REF.wang.2010">Wang et al 2010</a>] (<a href="http://jcn.sagepub.com/content/25/12/1559.long" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p><b>Early-onset <i>LAMA2</i> MD</b></p><ul><li class="half_rhythm"><div>At least biannual evaluations during the first five years by a nutritionist and gastroenterologist to monitor weight gain and to identify early recurrent aspiration</div></li><li class="half_rhythm"><div>At least annual follow up with a pulmonologist to assess respiratory function. After age four to six years: annual pulmonary function testing including assessment of forced vital capacity (FVC).</div></li><li class="half_rhythm"><div>Annual measurement of FVC to allow trending of FVC</div></li><li class="half_rhythm"><div>Annual evaluation of strength and joint range of motion by a physical therapist</div></li><li class="half_rhythm"><div>At least annual evaluation of the spine by an orthopedist. Note: (1) More frequent evaluations are warranted during periods of rapid growth, loss of function, and/or progression of deformities. (2) Annual lateral spinal x-rays (in addition to the standard anterior-posterior x-rays) can be used to evaluate the anterior posterior intra-thoracic cavity diameter; however, if respiratory function declines rapidly without known cause or without prior spinal surgery, a CT may be needed.</div></li><li class="half_rhythm"><div>Cardiac monitoring:</div><ul><li class="half_rhythm"><div>In the absence of symptoms, evaluation by a cardiologist including electrocardiogram and echocardiogram at age five years, ten years, and then every two years</div></li><li class="half_rhythm"><div>In patients with severe respiratory insufficiency on mechanical ventilation, annual echocardiography (required)</div></li><li class="half_rhythm"><div>In patients reporting palpitations, increased fatigue, or loss of consciousness without a clear neurologic origin, cardiac evaluation including Holter monitor and echocardiogram (recommended)</div></li><li class="half_rhythm"><div>Pre-surgical cardiac evaluation including Holter monitor, echocardiogram, and a dopamine test of cardiac function</div></li></ul></li></ul><p>Note: The brain MRI findings seen in both complete and partial laminin &#x003b1;2 deficiency do not need to be followed with serial scans over time [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>].</p><p><b>Late-onset <i>LAMA2</i> MD</b></p><ul><li class="half_rhythm"><div>Respiratory. Monitor for respiratory insufficiency with serial pulmonary function tests.</div></li><li class="half_rhythm"><div>Orthopedic. Monitor with frequent spinal examinations to detect scoliosis and assess bone health.</div></li><li class="half_rhythm"><div>Neurologic. Monitor to detect and treat seizures.</div></li></ul></div><div id="mdef-cmd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Succinylcholine in induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities</div></li><li class="half_rhythm"><div>Statin, cholesterol lowering medication, because of the risk of muscle damage</div></li></ul></div><div id="mdef-cmd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#mdef-cmd.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mdef-cmd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><i>LAMA2</i>-related muscular dystrophy leads to a primary deficiency of the protein laminin &#x003b1;2 in the extracellular matrix of muscle, precipitating several downstream effects including: increased inflammation, increased fibrosis, increased apoptosis, and decreased regeneration.</p><p>Several therapies have recently been tested in murine models that replicate disease pathogenesis (including the dyw and dy3k [neo cassettes in <i>LAMA2</i>] and dy2j [a spontaneously occurring <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>]). Current efforts to define standard operating protocols led by TREAT-NMD, a panel of international scientists and Cure CMD, have been posted at <a href="http://www.curecmd.org/resources-for-scientists" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">curecmd.org</a>.</p><p>Therapies currently under investigation target apoptosis with drugs such as omigapil [<a class="bk_pop" href="#mdef-cmd.REF.erb.2009.787">Erb et al 2009</a>] and doxycycline [<a class="bk_pop" href="#mdef-cmd.REF.girgenrath.2009.47">Girgenrath et al 2009</a>], and genetic manipulation of BAX [<a class="bk_pop" href="#mdef-cmd.REF.girgenrath.2004.1635">Girgenrath et al 2004</a>]. Additional approaches include protein replacement therapy using miniagrin constructs and pro-regenerative approaches using IgF [<a class="bk_pop" href="#mdef-cmd.REF.kumar.2011.2333">Kumar et al 2011</a>].</p><p>Another approach for the treatment of genetic disorders caused by premature termination codons is the use of drugs to force stop codon read-through [<a class="bk_pop" href="#mdef-cmd.REF.allamand.2008.217">Allamand et al 2008</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="mdef-cmd.Genetic_Counseling"><h2 id="_mdef-cmd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mdef-cmd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>LAMA2</i>-related muscular dystrophy (<i>LAMA2</i> MD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="mdef-cmd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <i>LAMA2</i> MD are obligate heterozygotes (carriers) for a pathogenic <i>LAMA2</i> variant.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="mdef-cmd.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p></div><div id="mdef-cmd.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mdef-cmd.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>LAMA2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Linkage and immunohistochemistry.</b> When two <i>LAMA2</i> pathogenic variants are not identified in the family, linkage analysis and evaluation of laminin &#x003b1;2 by immunohistochemical (IHC) staining in chorionic villi may be available in certain specialized laboratories [<a class="bk_pop" href="#mdef-cmd.REF.vainzof.2005.588">Vainzof et al 2005</a>].</p></div></div><div id="mdef-cmd.Resources"><h2 id="_mdef-cmd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association Francaise contre les Myopathies (AFM)</b></div><div>1 Rue de l'International</div><div>BP59</div><div>Evry cedex 91002</div><div>France</div><div><b>Phone:</b> +33 01 69 47 28 28</div><div><b>Email:</b> dmc@afm.genethon.fr</div><div><a href="http://www.afm-telethon.fr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.afm-telethon.fr </a></div></li><li class="half_rhythm"><div><b>Cure CMD</b></div><div>19401 South Vermont Avenue</div><div>Suite J100</div><div>Torrance CA 90502</div><div><b>Phone:</b> 323-250-2399</div><div><b>Fax:</b> 310-684-2023</div><div><b>Email:</b> info@curecmd.org</div><div><a href="http://www.curecmd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curecmd.org</a></div></li><li class="half_rhythm"><div><b>European Neuromuscular Centre (ENMC)</b></div><div>Lt Gen van Heutszlaan 6</div><div>3743 JN Baarn</div><div>Netherlands</div><div><b>Phone:</b> 31 35 5480481</div><div><b>Fax:</b> 31 35 5480499</div><div><b>Email:</b> enmc@enmc.org</div><div><a href="http://www.enmc.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.enmc.org</a></div></li><li class="half_rhythm"><div><b>Japan Muscular Dystrophy Association</b></div><div>3-43-11 Fukushi Zaidan Bldg</div><div> Tokyo 170-0005</div><div>Japan</div><div><b>Phone:</b> 81-3-6907-3521</div><div><a href="http://www.jmda.or.jp/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.jmda.or.jp</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li><li class="half_rhythm"><div><b>Congenital Muscle Disease International Registry (CMDIR)</b></div><div><i>The CMDIR is a patient self-report registry with the goal to register the global <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscle disease population including persons with congenital myopathy, congenital muscular dystrophy, and congenital myasthenic syndrome. The CMDIR registers <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of all ages with symptoms from birth through late onset (limb-girdle). Registrants will receive educational information and connections to others in the CMD community, and will be contacted about potential participation in clinical trials for their CMD subtype.</i></div><div>19401 South Vermont Avenue</div><div>Suite J100</div><div>Torrance CA 90502</div><div><b>Phone:</b> 323-250-2399</div><div><b>Fax:</b> 310-684-2023</div><div><b>Email:</b> counselor@cmdir.org; sarah.foye@cmdir.org</div><div><a href="http://www.cmdir.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cmdir.org</a></div></li></ul></div><div id="mdef-cmd.Molecular_Genetics"><h2 id="_mdef-cmd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mdef-cmd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>LAMA2-Related Muscular Dystrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97333/table/mdef-cmd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mdef-cmd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mdef-cmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3908" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LAMA2</i></a></td><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3908" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">6q22<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P24043" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Laminin subunit alpha-2</a></td><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/LAMA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA2 homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LAMA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA2</a></td><td headers="hd_b_mdef-cmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LAMA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LAMA2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mdef-cmd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mdef-cmd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for LAMA2-Related Muscular Dystrophy (<a href="/omim/156225,607855,618138" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97333/table/mdef-cmd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mdef-cmd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/156225" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">156225</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LAMININ, ALPHA-2; LAMA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607855" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607855</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/618138" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">618138</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 23; LGMDR23</td></tr></tbody></table></div></div><div id="mdef-cmd.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>LAMA2</i> MD is caused by deficiency in the basal lamina of muscle fibers of the &#x003b1;2 chain of laminins 2 and 4 (encoded by <i>LAMA2</i>). Hypotheses regarding the pathogenesis of <i>LAMA2</i> MD resulting in <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy include: disruption of cellular signaling; disruption of nerve-muscle interaction leading to denervation atrophy; and mechanical instability. The most likely hypothesis from studies with zebrafish is one of mechanical instability of the sarcolemma resulting in cellular damage and subsequent apoptosis [<a class="bk_pop" href="#mdef-cmd.REF.hall.2007.7092">Hall et al 2007</a>].</p><p><b>Gene structure.</b>
<i>LAMA2</i> spans 260 kb and the longest transcript variant (<a href="/nuccore/NM_000426.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000426.3</a>) has 65 exons and a very large <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> of 9.5 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK97333/#mdef-cmd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> The majority of pathogenic alleles are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, or <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants and small deletions, insertions, or duplications within exons that are readily detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and associated flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions. To date, 94 distinct pathogenic variants distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported in the <i>LAMA2</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>-specific database (<a href="/books/NBK97333/#mdef-cmd.molgen.TA">Table A</a>), the majority of which are small out-of-frame deletions (31.9%) and nonsense variants (29.8%). Others include splice variants (16.0%), missense substitutions (14.9%), and small duplications (7.4%) [<a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>].</p><p>Commonly reported pathogenic variants (exact prevalence in early-onset <i>LAMA2</i> MD population unknown) included in <a class="figpopup" href="/books/NBK97333/table/mdef-cmd.T.selected_lama2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figmdefcmdTselectedlama2pathogenicvar" rid-ob="figobmdefcmdTselectedlama2pathogenicvar">Table 2</a> are c.2901C&#x0003e;A, c.1854_1861dup, c.2048-2049del, c.7750-1713_78899-2153del4987 (<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 56), and c.7881T&#x0003e;G.</p><p>Commonly reported pathogenic variants (<a class="figpopup" href="/books/NBK97333/table/mdef-cmd.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figmdefcmdTmoleculargenetictestinguse" rid-ob="figobmdefcmdTmoleculargenetictestinguse">Table 1</a> and <a class="figpopup" href="/books/NBK97333/table/mdef-cmd.T.selected_lama2_pathogenic_var/?report=objectonly" target="object" rid-figpopup="figmdefcmdTselectedlama2pathogenicvar" rid-ob="figobmdefcmdTselectedlama2pathogenicvar">Table 2</a>) include the following:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant c.2901C&#x0003e;A that confers a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> ranging from sitting unsupported to ambulation with assistance depending on the type of variant in the second <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. c.2901C&#x0003e;A is reported as an Italian <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> [<a class="bk_pop" href="#mdef-cmd.REF.guicheney.1998.211">Guicheney et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>, <a class="bk_pop" href="#mdef-cmd.REF.di_blasi.2005.1582">Di Blasi et al 2005</a>, <a class="bk_pop" href="#mdef-cmd.REF.vigliano.2009.72">Vigliano et al 2009</a>].</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> c.1854_1861dup, associated with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> ranging from sitting unsupported to spastic gait [<a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>, <a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>]</div></li><li class="half_rhythm"><div>A 2-bp <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>, c.2048_2049del, associated with the ability to sit unsupported [<a class="bk_pop" href="#mdef-cmd.REF.pegoraro.1998.101">Pegoraro et al 1998</a>, <a class="bk_pop" href="#mdef-cmd.REF.hayashi.2001.350">Hayashi et al 2001</a>, <a class="bk_pop" href="#mdef-cmd.REF.allamand.2002.91">Allamand &#x00026; Guicheney 2002</a>]</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of ~5 kb (c.7750-1713_78899-2153del4987), identified in 31% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (N = 52 alleles). An <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> test was developed [<a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al 2008</a>].</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> Kenyan <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, c.7881T&#x0003e;G, associated with a variable clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh et al 2010</a>]</div></li></ul><div id="mdef-cmd.T.selected_lama2_pathogenic_var" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>LAMA2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK97333/table/mdef-cmd.T.selected_lama2_pathogenic_var/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mdef-cmd.T.selected_lama2_pathogenic_var_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2049_2050del<br />(2048_2049del&#x000a0;<sup>1</sup>)</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg683SerfsTer21</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_3" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000426.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000426<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000417.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000417<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2901C&#x0003e;A</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys976Ter</td></tr><tr><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1854_1861dup</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu621HisfsTer7</td></tr><tr><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7881T&#x0003e;G</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His2627Gln</td></tr><tr><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7750-1713_78899-2153del4987&#x000a0;<sup>2</sup><br />(~5 kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>)</td><td headers="hd_h_mdef-cmd.T.selected_lama2_pathogenic_var_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala2584HisfsTer8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mdef-cmd.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="mdef-cmd.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#mdef-cmd.REF.oliveira.2008.502">Oliveira et al [2008]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Laminins are a group of heterotrimeric glycoproteins composed of a heavy &#x003b1; chain and two light chains, &#x003b2; and &#x003b3;, each of which is encoded by a separate gene. To date, five &#x003b1; chains (designated &#x003b1;1 to &#x003b1;5), four &#x003b2; chains (&#x003b2;1 to &#x003b2;3), and three &#x003b3; chains (&#x003b3;1 to &#x003b3;3) have been identified, which combine to form 15 laminin <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>, each with tissue and/or developmental stage-specific expression [<a class="bk_pop" href="#mdef-cmd.REF.suzuki.2005.142">Suzuki et al 2005</a>]. In skeletal muscle, the predominant isoforms are laminin &#x003b1;2 (also known as merosin), which is composed of &#x003b1;2, &#x003b1;1, and &#x003b3;1 chains and laminin-4, composed of &#x003b1;2, &#x003b2;2, and &#x003b3;1 chains. Laminins are secreted into the extracellular matrix where they bind to neurexin, agrin, and collagen IV in the extracellular matrix and to dystroglycan and integrins in the sarcolemmal membrane [<a class="bk_pop" href="#mdef-cmd.REF.muntoni.2004.635">Muntoni &#x00026; Voit 2004</a>]. The biologic functions of laminins are varied and include cell-cell recognition, growth, differentiation, cell shape, and migration [<a class="bk_pop" href="#mdef-cmd.REF.suzuki.2005.142">Suzuki et al 2005</a>].</p><p><i>LAMA2</i> encodes a 400-kd protein that is post-translationally cleaved into 300-kd and 80-kd subunits, which remain associated by disulfide bonds. Laminin &#x003b1;2 is expressed in the striated muscle basement membrane, the cerebral blood vessels including the capillaries that form the blood-brain barrier, the glia limitans, the developing axon tracts, and Schwann cells.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>LAMA2</i> typically lead to early-onset <i>LAMA2</i> MD.</p></div></div><div id="mdef-cmd.References"><h2 id="_mdef-cmd_References_">References</h2><div id="mdef-cmd.Published_Guidelines__Consensus"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.wang.2010">Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, B&#x000e9;roud C, Bertini E, Bushby K,Cohn D, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R. Consensus statement on standard of care for congenital muscular dystrophies. Available <a href="http://jcn.sagepub.com/content/25/12/1559.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 10-23-19.</div></li></ul></div><div id="mdef-cmd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.alkan.2007.655">Alkan A, Sigirci A, Kutlu R, Aslan M, Doganay S, Yakinci C. Merosin-negative congenital muscular dystrophy: diffusion-weighted imaging findings of brain. <span><span class="ref-journal">J Child Neurol. </span>2007;<span class="ref-vol">22</span>:655–9.</span> [<a href="/pubmed/17690079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17690079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.allamand.2008.217">Allamand V, Bidou L, Arakawa M, Floquet C, Shiozuka M, Paturneau-Jouas M, Gartioux C, Butler-Browne GS, Mouly V, Rousset JP, Matsuda R, Ikeda D, Guicheney P. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. <span><span class="ref-journal">J Gene Med. </span>2008;<span class="ref-vol">10</span>:217–24.</span> [<a href="/pubmed/18074402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18074402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.allamand.2002.91">Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, <em>LAMA2</em> gene coding for alpha2 chain of laminin). <span><span class="ref-journal">Eur J Hum Genet. </span>2002;<span class="ref-vol">10</span>:91–4.</span> [<a href="/pubmed/11938437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11938437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.aslan.2005.308">Aslan M, Alkan A, Yakinci C, Sonmezgoz E, Bicak U, Zorludemir S. Merosin-negative Congenital muscular dystrophy: magnetic resonance spectroscopy findings. <span><span class="ref-journal">Brain Dev. </span>2005;<span class="ref-vol">27</span>:308–10.</span> [<a href="/pubmed/15862197" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15862197</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.bentley.2001.22">Bentley G, Haddad F, Bull TM, Seingry D. The treatment of scoliosis in muscular dystrophy using modified Luque and Harrington-Luque instrumentation. <span><span class="ref-journal">J Bone Joint Surg Br. </span>2001;<span class="ref-vol">83</span>:22–8.</span> [<a href="/pubmed/11245532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11245532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.carboni.2011.826">Carboni N, Marrosu G, Porcu M, Mateddu A, Solla E, Cocco E, Maioli MA, Oppo V, Piras R, Marrosu MG. Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin-&#x003b1;2-chain gene: a chance association or a novel phenotype? <span><span class="ref-journal">Muscle Nerve. </span>2011;<span class="ref-vol">44</span>:826–8.</span> [<a href="/pubmed/22006699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22006699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.darin.2000.1">Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. <span><span class="ref-journal">Neuromuscul Disord. </span>2000;<span class="ref-vol">10</span>:1–9.</span> [<a href="/pubmed/10677857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10677857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.di_blasi.2005.1582">Di Blasi C, Piga D, Brioschi P, Moroni I, Pini A, Ruggieri A, Zanotti S, Uziel G, Jarre L, Della Giustina E, Scuderi C, Jonsrud C, Mantegazza R, Morandi L, Mora M. <em>LAMA2</em> gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1582–6.</span> [<a href="/pubmed/16216942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16216942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.di_muzio.2003.500">Di Muzio A, De Angelis MV, Di Fulvio P, Ratti A, Pizzuti A, Stuppia L, Gambi D, Uncini A. Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. <span><span class="ref-journal">Muscle Nerve. </span>2003;<span class="ref-vol">27</span>:500–6.</span> [<a href="/pubmed/12661054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12661054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.erb.2009.787">Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Fr&#x000fc;h I, R&#x000fc;egg MA, Meier T. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2009;<span class="ref-vol">331</span>:787–95.</span> [<a href="/pubmed/19759319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19759319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.geranmayeh.2010.241">Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, Abbs S, Brueton L, Childs A-M, Jungbluth H, De Goede CG, Lynch B, Lin J-P, Chow G, de Sousa C, O&#x02019;Mahony O, Majumdar A, Straub V, Bushby K, Muntoni F. Genotype-phenotype correlation in a large population of muscular dystrophy patients with <em>LAMA2</em> mutations. <span><span class="ref-journal">Neuromuscul Disord. </span>2010;<span class="ref-vol">20</span>:241–50.</span> [<a href="/pubmed/20207543" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20207543</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.gilhuis.2002.30">Gilhuis HJ, ten Donkelaar HJ, Tanke RB, Vingerhoets DM, Zwarts MJ, Verrips A, Gabre&#x000eb;ls FJ. Nonmuscular involvement in merosin-negative congenital muscular dystrophy. <span><span class="ref-journal">Pediatr Neurol. </span>2002;<span class="ref-vol">26</span>:30–6.</span> [<a href="/pubmed/11814732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11814732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.girgenrath.2009.47">Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:47–56.</span> [<a href="/pmc/articles/PMC2639627/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2639627</span></a>] [<a href="/pubmed/19086074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19086074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.girgenrath.2004.1635">Girgenrath M, Dominov JA, Kostek CA, Miller JB. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. <span><span class="ref-journal">J Clin Invest. </span>2004;<span class="ref-vol">114</span>:1635–9.</span> [<a href="/pmc/articles/PMC529286/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC529286</span></a>] [<a href="/pubmed/15578095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15578095</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.gu_rin.2010.866">Gu&#x000e9;rin C, Vincent B, Petitjean T, Lecam P, Luizet C, Rabilloud M, Richard JC. The short-term effects of intermittent positive pressure breathing treatments on ventilation in patients with neuromuscular disease. <span><span class="ref-journal">Respir Care. </span>2010;<span class="ref-vol">55</span>:866–72.</span> [<a href="/pubmed/20587098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20587098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.guicheney.1998.211">Guicheney P, Vignier N, Zhang X, He Y, Cruaud C, Frey V, Helbling-Leclerc A, Richard P, Estournet B, Merlini L, Topaloglu H, Mora M, Harpey JP, Haenggeli CA, Barois A, Hainque B, Schwartz K, Tom&#x000e9; FM, Fardeau M, Tryggvason K. PCR based mutation screening of the laminin alpha2 chain gene (<em>LAMA2</em>): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy. <span><span class="ref-journal">J Med Genet. </span>1998;<span class="ref-vol">35</span>:211–7.</span> [<a href="/pmc/articles/PMC1051244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051244</span></a>] [<a href="/pubmed/9541105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9541105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.hall.2007.7092">Hall TE, Bryson-Richardson RJ, Berger S, Jacoby AS, Cole NJ, Hollway GE, Berger J, Currie PD. The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007;<span class="ref-vol">104</span>:7092–7.</span> [<a href="/pmc/articles/PMC1855385/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1855385</span></a>] [<a href="/pubmed/17438294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17438294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.hara.2011.939">Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltr&#x000e1;n-Valero de Bernab&#x000e9; D, G&#x000fc;nde&#x0015f;li H, Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, Talim B, Muntoni F, Topalo&#x0011f;lu H, Din&#x000e7;er P, Campbell KP. A dystroglycan mutation associated with limb-girdle muscular dystrophy. <span><span class="ref-journal">N Engl J Med. </span>2011;<span class="ref-vol">364</span>:939–46.</span> [<a href="/pmc/articles/PMC3071687/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3071687</span></a>] [<a href="/pubmed/21388311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21388311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.hayashi.2001.350">Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, Hoffman EP, Arahata K. Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2001;<span class="ref-vol">11</span>:350–9.</span> [<a href="/pubmed/11369186" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11369186</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.he.2001.1319">He Y, Jones KJ, Vignier N, Morgan G, Chevallay M, Barois A, Estournet-Mathiaud B, Hori H, Mizuta T, Tom&#x000e9; FM, North KN, Guicheney P. Congenital muscular dystrophy with primary partial laminin alpha2 chain deficiency: molecular study. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:1319–22.</span> [<a href="/pubmed/11591858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11591858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.jones.2001.649">Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, North KN. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:649–57.</span> [<a href="/pmc/articles/PMC1734735/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734735</span></a>] [<a href="/pubmed/11584042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11584042</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.jones.2012.e141">Jones LC, Waite PD. Orthognathic surgery and partial glossectomy in a patient with merosin-deficient congenital muscular dystrophy. <span><span class="ref-journal">J Oral Maxillofac Surg. </span>2012;<span class="ref-vol">70</span>:e141–6.</span> [<a href="/pubmed/22260916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22260916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.kumar.2011.2333">Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in <em>LAMA2</em> Dy-w mice, a model for congenital muscular dystrophy type 1A. <span><span class="ref-journal">Hum Mol Genet. </span>2011;<span class="ref-vol">20</span>:2333–43.</span> [<a href="/pmc/articles/PMC3098729/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3098729</span></a>] [<a href="/pubmed/21441569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21441569</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.leite.2005.190">Leite CC, Reed UC, Otaduy MC, Lacerda MT, Costa MO, Ferreira LG, Carvalho MS, Resende MB, Marie SK, Cerri GG. Congenital muscular dystrophy with merosin deficiency: 1H MR spectroscopy and diffusion-weighted MR imaging. <span><span class="ref-journal">Radiology. </span>2005;<span class="ref-vol">235</span>:190–6.</span> [<a href="/pubmed/15703311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15703311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.mellies.2005.543">Mellies U, Dohna-Schwake C, Voit T. Respiratory function assessment and intervention in neuromuscular disorders. <span><span class="ref-journal">Curr Opin Neurol. </span>2005;<span class="ref-vol">18</span>:543–7.</span> [<a href="/pubmed/16155437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16155437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.mellies.2003.123">Mellies U, Ragette R, Schwake C, Boehm H, Voit T, Teschler H. Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular disorders. <span><span class="ref-journal">Neuromuscul Disord. </span>2003;<span class="ref-vol">13</span>:123–8.</span> [<a href="/pubmed/12565909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12565909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.mercuri.1998.399">Mercuri E, Anker S, Philpot J, Sewry C, Dubowitz V, Muntoni F. Visual function in children with merosin-deficient and merosin-positive congenital muscular dystrophy. <span><span class="ref-journal">Pediatr Neurol. </span>1998;<span class="ref-vol">18</span>:399–401.</span> [<a href="/pubmed/9650678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9650678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.mercuri.2001.297">Mercuri E, Rutherford M, De Vile C, Counsell S, Sewry C, Brown S, Bydder G, Dubowitz V, Muntoni F. Early white matter changes on brain magnetic resonance imaging in a newborn affected by merosin-deficient congenital muscular dystrophy. <span><span class="ref-journal">Neuromuscul Disord. </span>2001;<span class="ref-vol">11</span>:297–9.</span> [<a href="/pubmed/11297945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11297945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.messina.2010.898">Messina S, Bruno C, Moroni I, Pegoraro E, D&#x02019;Amico A, Biancheri R, Berardinelli A, Boffi P, Cassandrini D, Farina L, Minetti C, Moggio M, Mongini T, Mottarelli E, Pane M, Pantaleoni C, Pichiecchio A, Pini A, Ricci E, Saredi S, Sframeli M, Tortorella G, Toscano A, Trevisan CP, Uggetti C, Vasco G, Comi GP, Santorelli FM, Bertini E, Mercuri E. Congenital muscular dystrophies with cognitive impairment. A population study. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:898–903.</span> [<a href="/pubmed/20820001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20820001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.mostacciuolo.1996.277">Mostacciuolo ML, Miorin M, Martinello F, Angelini C, Perini P, Trevisan CP. Genetic epidemiology of congenital muscular dystrophy in a sample from north east Italy. <span><span class="ref-journal">Hum Genet. </span>1996;<span class="ref-vol">97</span>:277–9.</span> [<a href="/pubmed/8786062" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8786062</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.muntoni.2004.635">Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. <span><span class="ref-journal">Neuromusc. Disord. </span>2004;<span class="ref-vol">14</span>:635–49.</span> [<a href="/pubmed/15351421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15351421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.naom.1998.495">Naom I, D&#x02019;Alessandro M, Sewry CA, Philpot J, Manzur AY, Dubowitz V, Muntoni F. Laminin alpha 2-chain gene mutations in two siblings presenting with limb-girdle muscular dystrophy. <span><span class="ref-journal">Neuromusc Disord. </span>1998;<span class="ref-vol">8</span>:495–501.</span> [<a href="/pubmed/9829280" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9829280</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.oliveira.2008.502">Oliveira J, Santos R, Soares-Silva I, Jorge P, Vieira E, Oliveira ME, Moreira A, Coelho T, Ferreira JC, Fonseca MJ, Barbosa C, Prats J, Ar&#x000ed;ztegui ML, Martins ML, Moreno T, Heinimann K, Barbot C, Pascual-Pascual SI, Cabral A, Fineza I, Santos M, Bronze-da-Rocha E. <em>LAMA2</em> gene analysis in a cohort of 26 congenital muscular dystrophy patients. <span><span class="ref-journal">Clin Genet. </span>2008;<span class="ref-vol">74</span>:502–12.</span> [<a href="/pubmed/18700894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18700894</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.pegoraro.1998.101">Pegoraro E, Marks H, Garcia CA, Crawford T, Mancias P, Connolly AM, Fanin M, Martinello F, Trevisan CP, Angelini C, Stella A, Scavina M, Munk RL, Servidei S, B&#x000f6;nnemann CC, Bertorini T, Acsadi G, Thompson CE, Gagnon D, Hoganson G, Carver V, Zimmerman RA, Hoffman EP. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. <span><span class="ref-journal">Neurology. </span>1998;<span class="ref-vol">51</span>:101–10.</span> [<a href="/pubmed/9674786" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9674786</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.philpot.1999a.542">Philpot J, Bagnall A, King C, Dubowitz V, Muntoni F. Feeding problems in merosin deficient congenital muscular dystrophy. <span><span class="ref-journal">Arch Dis Child. </span>1999a;<span class="ref-vol">80</span>:542–7.</span> [<a href="/pmc/articles/PMC1717951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1717951</span></a>] [<a href="/pubmed/10332004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10332004</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.philpot.1999b.81">Philpot J, Cowan F, Pennock J, Sewry C, Dubowitz V, Bydder G, Muntoni F. Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. <span><span class="ref-journal">Neuromuscul Disord. </span>1999b;<span class="ref-vol">9</span>:81–5.</span> [<a href="/pubmed/10220862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10220862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.pini.1996.316">Pini A, Merlini L, Tom&#x000e9; FM, Chevallay M, Gobbi G. Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families. <span><span class="ref-journal">Brain Dev. </span>1996;<span class="ref-vol">18</span>:316–22.</span> [<a href="/pubmed/8879653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8879653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.quijanoroy.2004.292">Quijano-Roy S, Renault F, Romero N, Guicheney P, Fardeau M, Estournet B. EMG and nerve conduction studies in children with congenital muscular dystrophy. <span><span class="ref-journal">Muscle Nerve. </span>2004;<span class="ref-vol">29</span>:292–9.</span> [<a href="/pubmed/14755496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14755496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.rajakulendran.2011.590">Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and pathological heterogeneity in late-onset partial merosin deficiency. <span><span class="ref-journal">Muscle Nerve. </span>2011;<span class="ref-vol">44</span>:590–3.</span> [<a href="/pubmed/21922472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21922472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.sewry.1997.169">Sewry CA, Naom I, D'Alessandro M, Sorokin L, Bruno S, Wilson LA, Dubowitz V, Muntoni F. Variable clinical phenotype in merosin-deficient congenital muscular dystrophy associated with differential immunolabelling of two fragments of the laminin alpha 2 chain. <span><span class="ref-journal">Neuromuscul Disord. </span>1997;<span class="ref-vol">7</span>:169–75.</span> [<a href="/pubmed/9185180" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9185180</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.siala.2007.199">Siala O, Louhichi N, Triki C, Morini&#x000e8;re M, Rebai A, Richard P, Guicheney P, Baklouti F, Fakhfakh F. Severe MDC1A congenital muscular dystrophy due to a splicing mutation in the LAMA2 gene resulting in exon skipping and significant decrease of mRNA level. <span><span class="ref-journal">Genet Test. </span>2007;<span class="ref-vol">11</span>:199–207.</span> [<a href="/pubmed/17949279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17949279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.spyrou.1998.474">Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. <span><span class="ref-journal">Am Heart J. </span>1998;<span class="ref-vol">136</span>:474–6.</span> [<a href="/pubmed/9736139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9736139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.sunada.1995.2084">Sunada Y, Edgar TS, Lotz BP, Rust RS, Campbell KP. Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities. <span><span class="ref-journal">Neurology. </span>1995;<span class="ref-vol">45</span>:2084–9.</span> [<a href="/pubmed/7501163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7501163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.suzuki.2005.142">Suzuki N, Yokoyama F, Nomizu M. Functional sites in the laminin alpha chains. <span><span class="ref-journal">Connect. Tissue Res. </span>2005;<span class="ref-vol">46</span>:142–52.</span> [<a href="/pubmed/16147852" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16147852</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.tezak.2003.103">Tezak Z, Prandini P, Boscaro M, Marin A, Devaney J, Marino M, Fanin M, Trevisan CP, Park J, Tyson W, Finkel R, Garcia C, Angelini C, Hoffman EP, Pegoraro E. Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (<em>LAMA2</em>) deficiency. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:103–11.</span> [<a href="/pubmed/12552556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12552556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.vainzof.2005.588">Vainzof M, Richard P, Herrmann R, Jimenez-Mallebrera C, Talim B, Yamamoto LU, Ledeuil C, Mein R, Abbs S, Brockington M, Romero NB, Zatz M, Topaloglu H, Voit T, Sewry C, Muntoni F, Guicheney P, Tom&#x000e9; FM. Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five international centers. <span><span class="ref-journal">Neuromuscul Disord. </span>2005;<span class="ref-vol">15</span>:588–94.</span> [<a href="/pubmed/16084089" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16084089</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.vigliano.2009.72">Vigliano P, Dassi P, Di Blasi C, Mora M, Jarre L. <em>LAMA2</em> stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2009;<span class="ref-vol">13</span>:72–6.</span> [<a href="/pubmed/18406646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18406646</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.wallgrenpettersson.2004.56">Wallgren-Pettersson C, Bushby K, Mellies U, Simonds A. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders -- congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands. <span><span class="ref-journal">Neuromuscul Disord. </span>2004;<span class="ref-vol">14</span>:56–69.</span> [<a href="/pubmed/14659414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14659414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mdef-cmd.REF.wang.2010.1559">Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, B&#x000e9;roud C, Bertini E, Bushby K, Cohn RD, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R., International Standard of Care Committee for Congenital Muscular Dystrophy.  Consensus statement on standard of care for congenital muscular dystrophies. <span><span class="ref-journal">J Child Neurol. </span>2010;<span class="ref-vol">25</span>:1559–81.</span> [<a href="/pmc/articles/PMC5207780/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5207780</span></a>] [<a href="/pubmed/21078917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21078917</span></a>]</div></li></ul></div></div><div id="mdef-cmd.Chapter_Notes"><h2 id="_mdef-cmd_Chapter_Notes_">Chapter Notes</h2><div id="mdef-cmd.Author_Notes"><h3>Author Notes</h3><p>Susan Sparks, MD, PhD is a board-certified pediatrician with additional board certifications in Clinical Genetics and Clinical Biochemical Genetics. At the Children&#x02019;s National Medical Center (CNMC) in Washington, DC under the direction of Dr Eric Hoffman at CNMC, Dr Sparks was awarded a Wellstone fellowship to do research in the clinical, molecular, and biochemical characterization of muscular dystrophies caused by a defect in O-linked glycan synthesis, a group known as the dystroglycanopathies. The dystroglycanopathies range clinically from <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> onset of muscular dystrophy with CNS and eye involvement, to a later onset form of limb-girdle muscular dystrophy (LGMD), without any CNS or eye involvement. Dr Sparks is also involved in the clinical characterization and evaluation of congenital muscular dystrophies and limb-girdle muscular dystrophies and has experience in preclinical and clinical trials in Duchenne muscular dystrophy. She is currently a medical director for genetic diseases with Genzyme, a Sanofi company.</p><p>Anne Rutkowski is chairman of Cure CMD, a nonprofit advocating for CMD awareness and treatment. Cure CMD is an all-volunteer organization that has led the path to building infrastructure to enable clinical trials, including the CMD International Registry (CMDIR) and CMD Care Guidelines. To get to clinical trials requires genetic confirmation and localization of the global CMD population. For more information, visit <a href="http://www.curecmd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.curecmd.org</a> and <a href="https://www.cmdir.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cmdir.org</a>.</p></div><div id="mdef-cmd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 June 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>16 March 2010 (ss) Initial submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK97333</span><span class="label">PMID: <a href="/pubmed/22675738" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">22675738</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/l1cam/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dcm-lmna/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK97333&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK97333/?report=reader">PubReader</a></li><li><a href="/books/NBK97333/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK97333" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK97333" style="display:none" title="Cite this Page"><div class="bk_tt">Quijano-Roy S, Sparks SE, Rutkowski A. LAMA2-Related Muscular Dystrophy. 2012 Jun 7. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK97333/pdf/Bookshelf_NBK97333.pdf">PDF version of this page</a> (524K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mdef-cmd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mdef-cmd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mdef-cmd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#mdef-cmd.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mdef-cmd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mdef-cmd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mdef-cmd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mdef-cmd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mdef-cmd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mdef-cmd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mdef-cmd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3908[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LAMA2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK97333+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2920038" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2920038" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2920038" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2920038" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301468" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31308722" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy.</a><span class="source">[Appl Clin Genet. 2019]</span><div class="brieflinkpop offscreen_noflow">Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nguyen Q, Lim KRQ, Yokota T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Appl Clin Genet. 2019; 12:113-130. Epub 2019 Jul 3.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301490" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Calpainopathy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Calpainopathy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Angelini C, Fanin M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301609" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Emery-Dreifuss Muscular Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bonne G, Leturcq F, Ben Yaou R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301676" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lampe AK, Flanigan KM, Bushby KM, Hicks D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=22675738" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=22675738" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040e1a75f66d18aaa57729">LAMA2-Related Muscular Dystrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">LAMA2-Related Muscular Dystrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:34:18-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D62DFE040392100000000046D0167&amp;ncbi_session=CE8D62DFE040E191_1133SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK97333%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK97333&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK97333/&amp;ncbi_pagename=LAMA2-Related Muscular Dystrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D62DFE040E191_1133SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>